Exhibit 99.2
WEBMD HEALTH CORP.
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data, unaudited)
Three Months Ended March 31, | ||||||||
2013 | 2012 | |||||||
Revenue | $ | 112,762 | $ | 106,947 | ||||
Cost of operations | 46,943 | 53,471 | ||||||
Sales and marketing | 30,933 | 30,103 | ||||||
General and administrative | 23,534 | 29,022 | ||||||
Depreciation and amortization | 6,853 | 6,930 | ||||||
Interest income | 21 | 11 | ||||||
Interest expense | 5,832 | 5,836 | ||||||
Gain on investments | — | 8,074 | ||||||
Other expense | — | 1,200 | ||||||
|
|
|
| |||||
Loss before income tax provision (benefit) | (1,312 | ) | (11,530 | ) | ||||
Income tax provision (benefit) | 226 | (3,753 | ) | |||||
|
|
|
| |||||
Net loss | $ | (1,538 | ) | $ | (7,777 | ) | ||
|
|
|
| |||||
Net loss per common share - Basic and Diluted | $ | (0.03 | ) | $ | (0.14 | ) | ||
|
|
|
| |||||
Weighted-average shares outstanding - Basic and Diluted | 49,007 | 55,769 | ||||||
|
|
|
|
WEBMD HEALTH CORP.
CONSOLIDATED SUPPLEMENTAL FINANCIAL INFORMATION
(In thousands, unaudited)
Three Months Ended March 31, | ||||||||
2013 | 2012 | |||||||
Revenue | ||||||||
Public portal advertising and sponsorship | $ | 93,438 | $ | 87,776 | ||||
Private portal services | 19,324 | 19,171 | ||||||
|
|
|
| |||||
$ | 112,762 | $ | 106,947 | |||||
|
|
|
| |||||
Earnings before interest, taxes, non-cash and other items (“Adjusted EBITDA”) (a) | $ | 21,289 | $ | 11,251 | ||||
Interest, taxes, non-cash and other items (b) | ||||||||
Interest income | 21 | 11 | ||||||
Interest expense | (5,832 | ) | (5,836 | ) | ||||
Income tax (provision) benefit | (226 | ) | 3,753 | |||||
Depreciation and amortization | (6,853 | ) | (6,930 | ) | ||||
Non-cash stock-based compensation | (9,937 | ) | (16,900 | ) | ||||
Gain on investments | — | 8,074 | ||||||
Other expense | — | (1,200 | ) | |||||
|
|
|
| |||||
Net loss | $ | (1,538 | ) | $ | (7,777 | ) | ||
|
|
|
|
(a) | See Annex A-Explanation of Non-GAAP Financial Measures. |
(b) | Reconciliation of Adjusted EBITDA to net loss. |
WEBMD HEALTH CORP.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands)
March 31, 2013 | December 31, 2012 | |||||||
(unaudited) | ||||||||
Assets | ||||||||
Cash and cash equivalents | $ | 999,221 | $ | 991,835 | ||||
Accounts receivable, net | 101,813 | 106,622 | ||||||
Prepaid expenses and other current assets | 14,999 | 13,882 | ||||||
Deferred tax assets | 10,339 | 10,328 | ||||||
|
|
|
| |||||
Total current assets | 1,126,372 | 1,122,667 | ||||||
Property and equipment, net | 62,808 | 66,604 | ||||||
Goodwill | 202,104 | 202,104 | ||||||
Intangible assets, net | 15,538 | 16,105 | ||||||
Deferred tax assets | 55,436 | 56,039 | ||||||
Other assets | 25,260 | 27,106 | ||||||
|
|
|
| |||||
Total Assets | $ | 1,487,518 | $ | 1,490,625 | ||||
|
|
|
| |||||
Liabilities and Stockholders’ Equity | ||||||||
Accrued expenses | $ | 49,107 | $ | 64,256 | ||||
Deferred revenue | 97,220 | 92,176 | ||||||
Liabilities of discontinued operations | 1,506 | 1,506 | ||||||
|
|
|
| |||||
Total current liabilities | 147,833 | 157,938 | ||||||
2.25% convertible notes due 2016 | 400,000 | 400,000 | ||||||
2.50% convertible notes due 2018 | 400,000 | 400,000 | ||||||
Other long-term liabilities | 22,742 | 22,698 | ||||||
Stockholders’ equity | 516,943 | 509,989 | ||||||
|
|
|
| |||||
Total Liabilities and Stockholders’ Equity | $ | 1,487,518 | $ | 1,490,625 | ||||
|
|
|
|
WEBMD HEALTH CORP.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands, unaudited)
Three Months Ended March 31, | ||||||||
2013 | 2012 | |||||||
Cash flows from operating activities: | ||||||||
Net loss | $ | (1,538 | ) | $ | (7,777 | ) | ||
Adjustments to reconcile net loss to net cash provided by operating activities: | ||||||||
Depreciation and amortization | 6,853 | 6,930 | ||||||
Non-cash interest, net | 1,082 | 1,082 | ||||||
Non-cash stock-based compensation | 9,937 | 16,900 | ||||||
Deferred income taxes | (99 | ) | (3,971 | ) | ||||
Gain on investments | — | (8,074 | ) | |||||
Changes in operating assets and liabilities: | ||||||||
Accounts receivable | 4,809 | 23,890 | ||||||
Prepaid expenses and other, net | (193 | ) | (4,023 | ) | ||||
Accrued expenses and other long-term liabilities | (14,850 | ) | (11,694 | ) | ||||
Deferred revenue | 5,044 | 2,266 | ||||||
|
|
|
| |||||
Net cash provided by operating activities | 11,045 | 15,529 | ||||||
Cash flows from investing activities: | ||||||||
Proceeds received from ARS option | — | 9,269 | ||||||
Purchases of property and equipment | (2,876 | ) | (3,377 | ) | ||||
|
|
|
| |||||
Net cash (used in) provided by investing activities | (2,876 | ) | 5,892 | |||||
Cash flows from financing activities: | ||||||||
Proceeds from exercise of stock options | 672 | 754 | ||||||
Cash used for withholding taxes due on stock-based awards | (174 | ) | (911 | ) | ||||
Purchases of treasury stock | (1,281 | ) | (415 | ) | ||||
|
|
|
| |||||
Net cash used in financing activities | (783 | ) | (572 | ) | ||||
|
|
|
| |||||
Net increase in cash and cash equivalents | �� | 7,386 | 20,849 | |||||
Cash and cash equivalents at beginning of period | 991,835 | 1,121,217 | ||||||
|
|
|
| |||||
Cash and cash equivalents at end of period | $ | 999,221 | $ | 1,142,066 | ||||
|
|
|
|